Group 1 - The capital market is experiencing a chain reaction, with Shandong Weiming Pharmaceutical Co., Ltd. (referred to as "Weiming Pharmaceutical") announcing significant stock price fluctuations and risk warnings due to abnormal trading activity [1] - Weiming Pharmaceutical expects a net loss attributable to shareholders of 55 million to 85 million yuan for the first half of 2025, representing a year-on-year decline of 85.72% to 187.02% [1] - The crisis is primarily due to the suspension of production and sales by its core subsidiary, Tianjin Weiming Biological Pharmaceutical Co., Ltd. (referred to as "Tianjin Weiming"), following a failure to meet GMP compliance requirements [1] Group 2 - Tianjin Weiming's production and sales of interferon drugs are the main source of revenue for Weiming Pharmaceutical, contributing 60% of the company's revenue in 2024 [2] - In 2024, Tianjin Weiming reported an operating income of 216 million yuan and a net loss of 14.0037 million yuan, significantly impacting Weiming Pharmaceutical's consolidated financial performance [2] - As of now, there are two A-share listed companies in Zibo under other risk warnings (ST), including Weiming Pharmaceutical and Shandong Lianchuang Industrial Development Group Co., Ltd. (referred to as "Lianchuang Shares") [2]

重要内容提示： 山东未名生物医药股份有限公司（以下简称"公司"）控股子公司天津未名 生物医药有限公司（以下简称"天津未名"）于 2025 年 4 月 22 日被采取暂停生 产、销售风险控制措施。2025 年 7 月 4 日，因试验进度未及预期，天津未名预 计在三个月内无法恢复正常生产经营活动，上述情形触及《深圳证券交易所股票 上市规则》（2025 年修订）中公司被实施其他风险警示的有关规定，公司股票交 易被实施其他风险警示，自 2025 年 7 月 8 日开市起，证券简称由"未名医药" 变更为"ST 未名"，股票交易日涨跌幅限制 5%。 证券代码：002581 证券简称：ST 未名 公告编号：2025-050 山东未名生物医药股份有限公司 关于股价异动及风险提示的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 公司股票日均换手率连续 2 个交易日与前 5 个交易日日均换手率比值达 335.81 倍，且累计换手率达 25.95%，根据深圳证券交易所的有关规定，属于股 票交易异常波动的情况。 二、公司关注并核实相关情况 针对公司 ...

Policy Developments - Shanghai is advancing the standardization research of medical accompaniment services, with a project led by East China Hospital identified as a key research topic for 2024, focusing on service institutions, personnel requirements, service processes, and quality evaluation [2] Drug and Device Approvals - Maike Bio has received a medical device registration certificate for its coagulation factor activity measurement kits, valid from July 8, 2025, to July 7, 2030, aimed at monitoring treatments for coagulation factor deficiencies [3] - Kewang Pharmaceutical's vitamin K1 drops have received a registration acceptance notice from the National Medical Products Administration, intended to prevent vitamin K deficiency bleeding in infants [4] - CanSino has been approved for clinical trials of its trivalent poliovirus vaccine, which is being developed using protein structure design and VLP assembly technology, currently undergoing I/II phase trials in Indonesia [5] Financial Reports - Johnson & Johnson reported Q2 revenue of $23.74 billion, a 5.8% increase year-over-year, exceeding market expectations, with projected annual sales between $93.2 billion and $93.6 billion [6] Capital Markets - Tuoxin Pharmaceutical plans to invest 10 million yuan in Jiangsu Jinsan Biotechnology Co., acquiring a 1.75% stake, with Jinsan successfully producing high-purity ergothioneine for various products [7] - Tsinghua Unigroup's stock auction resulted in the sale of 58.607 million shares, potentially leading to a change in control of the company, with the shares sold at an average price significantly above the latest closing price [8] Industry Events - China National Pharmaceutical Group responded to rumors regarding the "return" of a licensing agreement with Merck for a PD-1/VEGF bispecific antibody, stating that the collaboration is progressing normally and a milestone payment of $300 million is expected upon completion of technology transfer by 2025 [9] Public Sentiment Alerts - A senior executive of Astellas Pharma in China was sentenced to three and a half years in prison for espionage, highlighting potential risks in the pharmaceutical industry [10] Stock Market Alerts - ST Weiming's stock has been placed under risk warning due to a significant price drop and expected losses of 55 million to 85 million yuan for the first half of 2025, leading to a change in its trading name and restrictions on price fluctuations [11]

山东未名生物医药股份有限公司 关于股价异动及风险提示的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 山东未名生物医药股份有限公司（以下简称"公司"）控股子公司天津未名 生物医药有限公司（以下简称"天津未名"）于 2025 年 4 月 22 日被采取暂停生 产、销售风险控制措施。2025 年 7 月 4 日，因试验进度未及预期，天津未名预 计在三个月内无法恢复正常生产经营活动，上述情形触及《深圳证券交易所股票 上市规则》（2025 年修订）中公司被实施其他风险警示的有关规定，公司股票交 易被实施其他风险警示，自 2025 年 7 月 8 日开市起，证券简称由"未名医药" 变更为"ST 未名"，股票交易日涨跌幅限制 5%。 一、股票交易异常波动的情况 山东未名生物医药股份有限公司（以下简称"公司"）股票交易价格于 2025 年 7 月 11 日、2025 年 7 月 14 日、2025 年 7 月 15 日连续三个交易日收盘价格跌 幅累计偏离-14.84%，根据深圳证券交易所的有关规定，属于股票交易异常波动 的情况。 二、公司关注并核实相 ...

[Shandong Weiming Bio-Pharmaceutical Co., Ltd. 2025 Semi-Annual Performance Forecast](index=1&type=section&id=%E5%B1%B1%E4%B8%9C%E6%9C%AA%E5%90%8D%E7%94%9F%E7%89%A9%E5%8C%BB%E8%8D%AF%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B82025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) The company's 2025 semi-annual performance forecast indicates a significant expansion of net loss compared to the prior year [Expected Performance for the Current Period](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company expects to record a net loss for the first half of 2025, with the loss significantly expanding compared to the same period last year 2025 Semi-Annual Performance Forecast | Item | Current Reporting Period | Prior Year Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders of the Listed Company** | Loss: 55.00 million CNY - 85.00 million CNY | Loss: 29.6149 million CNY | | **Net Profit After Deducting Non-Recurring Gains and Losses** | Loss: 53.00 million CNY - 83.00 million CNY | Loss: 26.9934 million CNY | | **Basic Earnings Per Share** | Loss: 0.0834 CNY/share - 0.1288 CNY/share | Loss: 0.0449 CNY/share | [Communication with Accounting Firm](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) The company explicitly states that the financial data in this performance forecast is a preliminary estimate and has not been audited by a certified public accountant - The financial data related to this performance forecast has not been audited by a certified public accountant[4](index=4&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The primary reason for the expanded loss is the suspension of production and sales activities by subsidiary Tianjin Weiming, leading to a significant year-over-year decline in net profit attributable to the parent company - Net profit attributable to the parent company decreased by **85.72% to 187.02%** year-over-year during the reporting period, primarily due to the suspension of production and sales by subsidiary Tianjin Weiming[5](index=5&type=chunk) [Other Relevant Information](index=1&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company reminds investors that this performance forecast is a preliminary estimate by the finance department, and the final data will be subject to the 2025 semi-annual report to be disclosed, advising caution regarding investment risks - This performance forecast is a preliminary estimate by the company's finance department, unaudited, and the final data will be based on the 2025 semi-annual report, requiring investors to make cautious decisions[6](index=6&type=chunk)

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology sector, with a focus on innovative drug companies [2][3]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.82%, outperforming the CSI 300 index (0.82%) and the Wind All A index (1.71%). The market is currently focused on the expectations surrounding semi-annual reports and business development (BD) activities [8][9]. - The launch of the 2025 National Basic Medical Insurance and Commercial Health Insurance innovative drug directory is a significant development. This directory will include high-innovation drugs that provide substantial clinical value and patient benefits, which are not covered by basic medical insurance but recommended for commercial health insurance [3][13]. - The report highlights the importance of the commercial health insurance sector in the payment for innovative drugs, suggesting that the accessibility of high-priced innovative drugs is expected to improve, particularly in the areas of cell and gene therapy [3][13]. Market Weekly Review - The medical research outsourcing sector led the gains with a 9.29% increase, primarily driven by WuXi AppTec's positive semi-annual report announcement. Conversely, offline pharmacies and other biological products experienced declines of -1.29% and -1.55%, respectively [8][9]. - Notable stock performances included Frontier Biotech-U (41.4%), Mediso (38.9%), and Lianhuan Pharmaceutical (38.6%) leading the gains, while ST Unimed (-18.5%), Shenzhou Cell-U (-13.4%), and Shutai Shen (-11.6%) faced significant losses [11][12]. Industry News and Key Company Announcements - The report outlines several key industry events, including the approval of innovative drugs and strategic partnerships among major pharmaceutical companies, which are expected to enhance their market positions and product offerings [13][16][17]. - The report also mentions significant financial forecasts from various companies, indicating strong growth potential in the sector, with some companies projecting net profit increases of over 100% year-on-year [17][18].

Market Activity - On July 11, the A-share market showed active trends with 61 stocks hitting the daily limit up, and a total of 17 stocks achieved consecutive limit ups, resulting in a success rate of 69% for limit orders [1] - The market focused on several strong stocks, with Sifang New Materials achieving a remarkable five consecutive limit ups, and Guotou Zhonglu also performing well with a T-shaped limit up, reaching five consecutive limit ups [1] - Stocks like Jingyi Co. and Yamaton achieved their fifth limit up within eight trading days through reverse limit up strategies [1] Stock Performance - Among the stocks with consecutive limit ups, Forest Packaging demonstrated a strong performance with seven consecutive limit ups, while companies like Shuangwei New Materials, Nanhua Futures, and Hemei Group achieved three consecutive limit ups [1] - ST Yazhen maintained an impressive performance with 12 limit ups over 15 days, while Yamaton and Jingyi Co. kept a pace of five limit ups over eight days [2] Market Sentiment and Capital Inflow - The market showed positive sentiment with active participation from investors, as evidenced by over 15 billion yuan in limit order funds supporting Shuangwei New Materials, and several other stocks like Sifang New Materials and Jin'an Guoji also receiving billions in limit order funds [1] - The total trading volume in the Shanghai and Shenzhen markets exceeded 1.7 trillion yuan, marking the highest level in nearly four months, indicating a significant increase in overall market activity and investor engagement [1] Sector Performance - The non-ferrous metal sector was notably active, with stocks like Hunan Silver and China Nonferrous Metals achieving limit ups [1] - The rare earth permanent magnet sector also showed strength, with companies like Northern Rare Earth and Jingyuntong achieving two consecutive limit ups, while Baogang Group and China Rare Earth also hit limit ups [1] - The securities IT sector attracted capital interest, with stocks like Jinzhen Co. and Guo'ao Technology hitting limit ups [1]

Group 1 - ST Unimed (002581) has been placed under other risk warnings due to its subsidiary Tianjin Unimed Biopharmaceutical Co., Ltd. being unable to resume normal operations within three months, leading to a stock suspension on July 7 and a subsequent name change to "ST Unimed" upon resumption [1] - The company's board acknowledges the negative impact of this situation and is taking effective measures to mitigate uncertainties, including cooperating with regulatory authorities for defect rectification and optimizing management to enhance profitability [1] - The company has completed a capital increase of 45 million yuan in its wholly-owned subsidiary Peking University Unimed (Shanghai) Biopharmaceutical Co., Ltd., acquiring a 51% stake in Sichuan Gukang Pharmaceutical Co., Ltd., which is expected to contribute revenue and profit starting from the 2025 semi-annual report [1] Group 2 - Sichuan Gukang Pharmaceutical, established in 2012, focuses on the procurement, processing, research, and sales of traditional Chinese medicine, offering over 400 high-quality products [2] - In 2024, Gukang Pharmaceutical reported revenues of 73.93 million yuan and a net profit of 4.15 million yuan, with a significant increase in performance expected in 2025, as revenues from January to April 2025 already surpassed the entire 2024 net profit [2] - The acquisition aims to enhance the pharmaceutical supply chain and explore opportunities in traditional Chinese medicine, leveraging Gukang's established market presence and customer resources to create synergies with existing business [2] Group 3 - The company is also making progress in its own operations, with a focus on strengthening its professional R&D platform, particularly through its subsidiary Shandong Yandu Biotechnology Co., Ltd. [3] - Shandong Yandu has developed a high-expression recombinant protein platform and is advancing multiple drug research systems, including a new ophthalmic drug that has completed Phase II clinical trials and is preparing for Phase III [3] - The core product, injectable mouse nerve growth factor, generated approximately 139 million yuan in revenue in 2024, while the new ophthalmic drug, a second-generation recombinant human nerve growth factor, has high clinical value and potential to become the first recombinant human nerve growth factor eye drop in China [3]

Core Viewpoint - Shandong Weiming Pharmaceutical Co., Ltd. faces significant operational challenges due to the suspension of production and sales at its subsidiary Tianjin Weiming Biopharmaceutical Co., Ltd., leading to a risk warning for its stock and a change in trading status to "ST Weiming" [1][3]. Group 1: Stock Trading and Risk Warnings - Tianjin Weiming was subjected to risk control measures on April 22, 2025, and is expected to be unable to resume normal operations within three months as of July 4, 2025, triggering a risk warning under the Shenzhen Stock Exchange regulations [1][3]. - The company's stock price experienced a cumulative decline of 15.82% over three consecutive trading days starting July 8, 2025, indicating abnormal trading fluctuations [1][2]. Group 2: Financial Impact and Company Performance - In 2024, Tianjin Weiming generated revenue of RMB 216.57 million and incurred a net loss of RMB 14.00 million, accounting for 60.09% of the company's total revenue and 9.8% of the consolidated net profit [2]. - For the fiscal year 2024, the company reported total revenue of RMB 360.41 million and a net loss attributable to shareholders of RMB 137.31 million, with the first quarter of 2025 showing revenue of RMB 35.33 million and a continued net loss [3].

山东未名生物医药股份有限公司（以下简称"公司"）控股子公司天津未名 生物医药有限公司（以下简称"天津未名"）于 2025 年 4 月 22 日被采取暂停生 产、销售风险控制措施。2025 年 7 月 4 日，因试验进度未及预期，天津未名预 计在三个月内无法恢复正常生产经营活动，上述情形触及《深圳证券交易所股票 上市规则》（2025 年修订）中公司被实施其他风险警示的有关规定，公司股票交 易被实施其他风险警示，自 2025 年 7 月 8 日开市起，证券简称由"未名医药" 变更为"ST 未名"，股票交易日涨跌幅限制 5%。 证券代码：002581 证券简称：未名医药 公告编号：2025-047 山东未名生物医药股份有限公司 关于股价异动及风险提示的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 一、股票交易异常波动的情况 山东未名生物医药股份有限公司（以下简称"公司"）股票交易价格于 2025 年 7 月 8 日、2025 年 7 月 9 日、2025 年 7 月 10 日连续三个交易日收盘价格跌幅 累计偏离-15.82%，根据深圳证券交 ...